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Abstract
Background: Breast cancer patients are at a four-fold increased risk of developing a venous thromboembolism
(VTE), a major cause of death in this group. Conversely, coagulation factors promote tumour growth and metastasis.
This has been evidenced in preclinical models, with an inhibitory effect of anticoagulants on cancer growth
through proliferative, angiogenic, apoptotic, cancer stem cell and metastatic processes. The extrinsic clotting
pathway is also more upregulated in patients in the relatively poorer prognosis oestrogen receptor (ER)-negative
breast cancer subgroup, with increased tumour stromal expression of the coagulation factors Tissue Factor and
thrombin.
Rivaroxaban (Xarelto®, Bayer AG, Leverkusen, Germany) is a direct oral anticoagulant (DOAC). It is a Factor Xa
inhibitor that is routinely prescribed for the prevention of stroke in non-valvular atrial fibrillation and for both VTE
prophylaxis and treatment. This trial will assess the anti-proliferative and other anti-cancer progression mechanisms
of Rivaroxaban in ER-negative early breast cancer patients.
Methods: This UK-based preoperative window-of-opportunity phase II randomised control trial will randomise 88
treatment-naïve early breast cancer patients to receive 20 mg OD Rivaroxaban treatment for 11 to 17 days or no
treatment. Treatment will be stopped 24 h (range 18–36 h) prior to surgery or repeat core biopsy. All patients will
be followed up for 2 weeks following surgery or repeat core biopsy.
The primary endpoint is change in tumour Ki67. Secondary outcome measures include tumour markers of
apoptosis and angiogenesis, extrinsic clotting pathway activation and systemic markers of metastasis, tumour load
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and coagulation.
Discussion: Laboratory evidence supports an anti-cancer role for anticoagulants; however, this has failed to
translate into survival benefit when trialled in patients with metastatic disease or poor prognosis cancers, such as
lung cancer. Subgroup analysis supported a potential survival benefit in better prognosis advanced disease patients.
This is the first study to investigate the anti-cancer effects of anticoagulants in early breast cancer.
Trial registration: UK National Research Ethics Service (NRES) approval 15/NW/0406, MHRA Clinical Trials
Authorisation 48380/0003/001-0001. The sponsor is Manchester University NHS Foundation Trust, and the trial is co-
ordinated by Cancer Research UK Liverpool Cancer Trials Unit (LCTU). EudraCT 2014-004909-33, registered 27 July
2015. ISRCTN14785273.
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Background
Breast cancer in women is associated with a four-fold in-
creased risk of venous thromboembolism (VTE) com-
pared to age-matched women without cancer [1, 2].
Chemotherapy-induced VTE occurs in up to 7% of early
breast cancer and 17% of metastatic breast cancer pa-
tients [3]. Breast cancer patients who develop VTE have
a worse survival, which cannot solely be accounted for
by VTE-induced mortality [4, 5]. It is thought to in part
be due to a promotion of cancer growth and metastasis
by coagulation factors.
Tissue Factor (TF), a transmembrane glycoprotein, is
the initiator of the extrinsic clotting cascade. TF binds to
plasma factor VII/VIIa (FVII/VIIa) to initiate coagulation
via activation of Factor X (FX). This leads to the gener-
ation of thrombin, fibrin deposition and clot formation,
as well as platelet activation (Fig. 1). In addition to its
haemostatic role, TF activates cell signalling through TF:
FVIIa and TF:FVIIa:FXa cleaving of the G-coupled
protease-activated receptor (PARs) 1 and 2 complexes.
TF directly promotes tumour growth, migration and
angiogenesis via activation of the PAR-2 receptor [7–11].
Thrombin can also modify tumour cell behaviour, directly
through the activation of PAR receptors, indirectly by acting
on stromal cells, or by the generation of fibrin matrices [12–
14]. Thrombin promotes tumour growth in vitro [15] and
in vivo [16–18], enhances tumour adhesion to platelets [16,
17, 19] and endothelial cells [20] in vitro and increases ex-
perimental (tail-vein injection) metastasis [16, 17, 19, 21].
Thrombin also increases tumour cell motility [22]. TF [23]
and thrombin [24] promote neo-angiogenesis via upregula-
tion of VEGF (a potent angiogenic factor) in cancer cells
through the PI3K/Akt pathway [25]. TF also downregulates
anti-angiogenic factors such as thrombospondin-1 and
thrombospondin-2 [26], while thrombin upregulates matrix
metalloproteinase-2 [27]. TF and thrombin also activate
angiogenesis by clotting-dependent mechanisms through
production (via thrombin) of polymerised fibrin which pro-
vides a scaffold around tumours to support and stimulate
endothelial cell proliferation [28]. In clinical studies, TF
expression correlates with VEGF expression and markers of
angiogenesis [29], while prothrombin fragments (produced
when prothrombin is converted to active thrombin) closely
associate with areas of neo-angiogenesis at the tumour-
stroma interface [30, 31].
Cancer cells express high levels of TF, thrombin and
PARs [32, 33]. Breast cancer expression of TF has been re-
ported to be an independent predictor of overall survival
[34]. Plasma D-dimer (fibrin degradation by-product) is
increased in breast cancer and correlates with tumour
stage, poor prognosis molecular phenotypes oestrogen re-
ceptor (ER) negative, human epidermal growth factor re-
ceptor 2 (HER-2) positive [35, 36], circulating tumour
cells [37, 38] and reduced survival [39]. D-dimer also has
potential as a pharmacodynamic biomarker for chemo-
therapy response [40].
In a prospective cohort study of 248 early breast can-
cer patients, we found that tumour fibroblast expression
of TF was increased in patients with primary breast can-
cer as compared to both ductal carcinoma in situ (DCIS)
and normal breast. We also found that fibroblast TF,
thrombin, PAR-1 and PAR-2 expression were increased
in patients with ER-negative, HER-2-positive and high
Ki67 tumours [41].
Inhibition of this coagulation cascade could therefore be
a therapeutic option in breast cancer patients. A Cochrane
review in 2011 reported that parenteral anticoagulation
(with either unfractionated heparin or low molecular
weight heparin) for patients with cancer, who have no
therapeutic or prophylactic indication for anticoagulation,
resulted in a statistically and clinically significant reduc-
tion in mortality at 24months. This demonstrates a po-
tential anti-cancer effect of anticoagulants in patients with
better prognosis metastatic disease [42].
Direct oral anticoagulants (DOACs) inhibit thrombin
(e.g. dabigatran etexilate (Pradaxa®)) or its activating en-
zyme Factor Xa (e.g. Rivaroxaban). DOACs have come
into regular clinical use in the last decade for the pre-
vention of VTE in orthopaedic surgery and of stroke in
non-valvular atrial fibrillation [43, 44]. DOACs are also
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used for the treatment of primary or recurrent VTE.
DOACs target a specific single enzyme within the extrin-
sic clotting pathway unlike the more widespread effects of
heparins and vitamin K antagonists (Warfarin). A meta-
analysis of randomised controlled trials of VTE-treatment
with DOACs in cancer patients has indicated they are as
safe and effective as conventional treatments [45].
Rivaroxaban was the first orally active direct Factor Xa
inhibitor and, through inhibition of the Tissue Factor-
Factor VIIa-Factor Xa complex, inhibits the conversion
of prothrombin to thrombin [46]. Rivaroxaban is well
absorbed from the gut and maximum inhibition of Fac-
tor Xa occurs 1 to 4 h after administration [47, 48]. Riv-
aroxaban has shown comparable safety to heparin for
thromboprophylaxis after total hip replacements, with
the convenience of oral dosing and reduced coagulation
monitoring [49]. Rivaroxaban has the potential to down-
regulate the TF-FVIIa-FXa complex activation of PAR-2
and the subsequent tumour cell migration and produc-
tion of pro-angiogenic and immune-modulating cyto-
kines, chemokines and growth factors [10]. Rivaroxaban
was chosen as the DOAC for this window-of-
opportunity study as it inhibits the coagulation cascade
at its origin and has a good safety profile. We have also
found that Rivaroxaban inhibits cancer stem cell (CSC)
activity in the in vitro functional CSC assay of mammo-
sphere formation [50].
In summary, in vitro and in vivo evidence supports a
potential inhibitory effect of anticoagulants on cancer
growth through proliferative, cancer stem cell, angio-
genic and metastatic processes. ER-negative early breast
cancer patients have a relatively poorer prognosis and
higher stage at diagnosis with an associated reduced
disease-free survival. ER-negative early breast cancer pa-
tients also have fewer options for adjuvant therapy. Our
previous data supports the hypothesis that the extrinsic
clotting pathway is more upregulated in the ER-negative
breast cancer subgroup as compared to ER-positive
breast cancer, and thereby provides a potential thera-
peutic strategy.
To test a novel therapy in the adjuvant breast cancer
setting would require thousands of patients, long follow-
up and great expense. The alternative is the more novel
‘window-of-opportunity’ clinical trial design where drugs
are tested over a short period, in the preoperative set-
ting. Biomarkers are used as early markers for response
and long-term outcome. Ki67 (tumour proliferation
marker) is recognised as such a marker in trials of
Fig. 1 The extrinsic coagulation pathway. Tissue Factor (TF), the main initiator of the coagulation cascade, complexes with Factor VIIa to activate
Factor X, and in turn converts prothrombin (PT) to thrombin (Th) and ultimately fibrinogen to fibrin, with subsequent clot formation. FXa is
inhibited by the direct oral anticoagulant Rivaroxaban. Thrombin also binds to protease-activated receptor 1 (PAR-1), and the TF/FVIIa/Xa complex
to PAR-2. In cancer cells, this is proposed to result in pro-angiogenic, pro-proliferative and pro-invasive gene expression resulting in increased
metastases. Figure created with BioRender.com [6]. Abbreviations: TF, Tissue Factor; FVIIa, activated Factor VII; FX, Factor X; FXa, activated Factor X;
PT, prothrombin; Th, thrombin; PAR, protease-activated receptor
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endocrine therapy. Short-term neoadjuvant studies have
demonstrated that only 2 weeks of preoperative endo-
crine therapy induces changes in Ki67 which predicts for
treatment benefit and long-term survival outcome [51].
By using biomarkers, we may be able to demonstrate the
potential effectiveness of an anticoagulant in the clinical
setting to support future larger adjuvant trials.
The TIP Trial will assess the anti-proliferative and
other anti-cancer progression mechanisms of Rivaroxa-
ban in ER-negative early breast cancer patients.
Methods
This study protocol has been reported in accordance
with the Standard Protocol Items: Recommendations for
Clinical Interventional Trials (SPIRIT) guidelines
(Additional file 1).
Aim
The primary aim of the Thrombin Inhibition Preopera-
tively in Early Breast Cancer (TIP) trial is to determine
whether preoperative administration of the oral Factor
Xa inhibitor Rivaroxaban results in inhibition of tumour
proliferation markers, as determined by a reduction in
tumour Ki67 from baseline (pre-treatment) to post treat-
ment (‘end-of-trial’, at time of surgical excision or repeat
core biopsy prior to neoadjuvant chemotherapy), in ER-
negative early breast cancer patients.
Study design
The TIP trial is a phase II preoperative window-of-
opportunity randomised controlled trial of Rivaroxaban
compared to no treatment in ER-negative stage I–III early
breast cancer patients.
This UK-based multi-centre study will randomise 88
eligible patients (1:1) to either Rivaroxaban 20mg once
daily (OD) or no treatment (control). Randomisation will
be blinded to pathologists and data analysts, but not to
patients or clinicians.
Sample size calculation
The trial is designed with a two-sided alpha level of 0.05
and an estimated 80% power to detect a 0.6 standard de-
viation (SD) reduction in percentage tissue expression of
Ki67 in early breast cancer patients treated with Rivarox-
aban. Based on a two-sample t test with this 80% power,
88 eligible patients are required. We will allow for a 10%
drop out rate, and therefore, 8 extra patients (giving a
total of 96 patients) may need to be recruited. Any pa-
tient that withdraws from the trial or does not have sur-
gery or a repeat core biopsy following treatment will be
removed from the study and replaced.
Participants
Females aged 18 years or over with newly diagnosed
early-stage breast cancer (stages I–III) that have a
tumour of size ≥ 10mm and are oestrogen receptor
negative (ER−) as defined by an ER QuickScore/Allred
Score ≤ 5 will be eligible to participate in the TIP trial.
Exclusion criteria include factors related to slow drug
excretion (e.g. poor renal function), drug interactions
(e.g. azole-antimycotics) and risk factors for bleeding
(e.g. recent major surgery).
Screening for eligibility
Assessments for patient eligibility to participate in the
trial are completed prior to patient randomisation. These
include blood biochemistry, liver function tests, baseline
tumour assessment as per National Health Service
Breast Screening Programme guidelines [52] and histo-
pathological core biopsy including ER/PR receptor sta-
tus. An electronic screening log is used to record each
patient screened for the trial (even if not approached)
and whether or not they were recruited.
Randomisation
Patients will be randomly assigned (1:1) to either the
control or intervention arm. Randomisation will be car-
ried out centrally at the Liverpool Cancer Trials Centre
(LCTC) based on pre-specified randomisation lists. The
sequence of allocations is produced using the Stata pack-
age ralloc employing permutated block randomisation
with block length of 4, 6 and 8. There are no stratifica-
tion factors to be considered.
Intervention group
Patients randomised to the intervention arm will receive
Rivaroxaban 20mg once daily for 11–17 days after diag-
nosis, prior to further treatment in the form of surgery
or neo-adjuvant chemotherapy (NAC). Patients with
planned NAC consent to undergo a repeat core biopsy
once the trial treatment period has been completed.
Rivaroxaban treatment is stopped 24 h (range 18–36 h)
prior to surgery or repeat core biopsy before commen-
cing NAC (Figs. 2 and 3). The dose of 20 mg OD was
chosen as this is the licenced dose in the UK for the pre-
vention of stroke and systemic embolism in adult pa-
tients with non-valvular atrial fibrillation with one or
more risk factors [53]. No other concurrent neoadjuvant
breast cancer or anticoagulant therapy is permitted.
All patients in the intervention arm will have an alert
sticker placed in their notes to ensure that the medical
team are aware that the patient has been anticoagulated
and take all necessary precautions to minimise bleeding
in the event of any residual anticoagulant effect.
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Modifications to the rivaroxaban dose are not allowed;
the intervention will simply be discontinued upon pres-
entation with unacceptable toxicity.
Control group
Patients randomised to the control group will not re-
ceive any anticoagulant therapy between diagnosis and
either surgery or repeat biopsy prior to commencing
NAC. They will receive current standard of care.
The use of a blinded placebo plus usual care compara-
tor was considered in trial design but was decided
against given the TIP trial has a biological endpoint
(Ki67). Clinicians (surgeons or radiologists performing
biopsies) are not to be blinded as a safety measure, but
laboratory staff and data analysts will be blinded to avoid
bias.
Procedure
Following randomisation, all patients receive a copy of
their signed consent form, a patient information sheet
and a patient contact card. Residual tissue from the
formalin-fixed paraffin-embedded pre-treatment diag-
nostic core biopsy tissue which is routinely stored will
be requested for trial purposes and a 35-ml venous
blood sample collected.
Upon termination of Rivaroxaban treatment or none,
residual formalin-fixed and fresh tumour tissue will be
obtained from trial patients undergoing surgery after
routine clinical processing or from the repeat research
biopsy prior to NAC.
All post-trial care, including provision for compensa-
tion, is through the NHS standard care pathway and
NHS channels.
Patient and public involvement
Patient and public representatives (PPI) were involved in
the set-up of the trial, and a patient representative will
take part in Trial Steering Committee meetings. PPI in-
dicated to us that the trial risk was minimal and
acceptable.
Measures
Pathologists, research laboratory staff and data analysts
will be blinded to patient randomisation in the TIP trial




The primary outcome measure of the TIP trial is to de-
termine the absolute and percentage change in the
tumour tissue expression of the biomarker Ki67 before
and after Rivaroxaban treatment, with the control arm
acting as a reference group.
The completely specified primary outcome measure as
defined by the five elements set out by Saldanha et al.
[54]: (1) Domain: Breast cancer tumour cell proliferation.
(2) Specific measurement: Immunohistochemical assess-
ment of the proportion (%) of cells staining for the nu-
clear antigen Ki67. (3) Metric: Absolute and percentage
Fig. 2 Thrombin Inhibition Preoperatively (TIP) in Early Breast Cancer Trial flow diagram. In this multi-centre study patients are randomised 1:1 20
mg Rivaroxaban once daily (OD): No Treatment. Randomisation is blinded to pathologists, research laboratory staff and data analysts, but not to
patients and clinicians
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change from baseline. (4) Method of aggregation: Mean.
(5) Time point: Post-treatment (‘end-of-trial’, 14 days
range 11–17, at time of surgical excision or repeat core
biopsy prior to neoadjuvant chemotherapy).
Secondary outcome measures
A range of potential breast cancer pharmacodynamic
biomarkers will be studied as secondary outcome
measures:
1. Primary mammosphere formation assays will be
performed ex vivo on fresh tumour tissue at the
end-of-trial time-point to determine cancer stem
cell activity. This data will be presented as a com-
parison of the means of mammosphere forming effi-
ciency (MFE) in the intervention and control arms.
MFE is calculated by dividing the number of
mammospheres formed at 7 days by the number of
cells seeded [55].
2. Formalin-fixed paraffin-embedded (FFPE) tissue will
be assessed for tumour markers of angiogenesis
(CD31), apoptosis (Cleaved caspase 3, TUNEL) and
the extrinsic clotting pathway (Tissue Factor,
thrombin, PAR-1; in both epithelial cells/fibroblasts)
by immunohistochemistry. Baseline core biopsy
samples and end-of-trial biopsy samples will be
assessed, and mean values analysed.
3. Plasma biomarkers of coagulation (Tissue Factor,
thrombin and d-dimer) will be quantified by
enzyme-linked immunosorbent assay (ELISA)
with the change from baseline to the end-of-trial
time-point assessed. Mean biomarker will be
compared between the control and intervention
arms.
STUDY PERIOD
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Fig. 3 TIP Trial Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure. Abbreviations: mg, milligram; OD, once daily
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4. FFPE tissue and plasma will be stored for future
translational research, for example ctDNA, with
patient consent.
Trial tumour tissue, plasma and serum samples, both
for short-term storage and for future translational re-
search, will be stored in temperature-controlled facilities
at the Oglesby Cancer Research Building in Manchester,
UK. This patient material will all be stored according to
Good Clinical Laboratory Practise (GCLP) guidelines [56].
Analysis
Both primary and secondary analyses will be carried out
on an intention to treat (ITT) basis. Missing data or
missing patients’ samples will be minimised by active
monitoring by the Trial Coordinator, regularly reviewed
by the Trial Management Group (TMG), including
scheduled data cleaning, sample checking and communi-
cations with trial sites. If samples for the primary end-
point analysis are not collected, the patient will be
replaced. Any patients who withdraw from the trial will
be replaced. If the level of missing data exceeds these
safeguards, it may be handled by multiple imputation.
Separate multiple imputations by treatment arm would
be performed, using the method of chained equations.
Ki67
Manual Section Score Ki67 will be compared between
arms using a beta regression model including terms ac-
counting for baseline Ki67, treatment arm, and covari-
ates known to be associated with Ki67 such as tumour
grade and HER-2 status. Although the sample size is
based on a t test, a beta regression model for the analysis
is superior, partly because the analysis would be on the
original scale, partly because covariates including base-
line would be easily accounted for and partly because
treatment effects on variance could be explicitly mod-
elled. Ki67 measurements will be performed in accord-
ance with national guidance [57].
Data management
The paper Case Report Form (CRF) distributed by the
LCTU is the primary data collection instrument for the
study and is completed by delegated site staff. The ac-
curacy of these CRFs are the responsibility of the Princi-
pal Investigator at each site. CRF data is entered into an
electronic database manually from the paper forms by
LCTU staff. There is central monitoring by the LCTU to
ensure that any data collected is compliant with the trial
protocol. The database used for this trial includes valid-
ation features which will alert the user to certain incon-
sistent or missing data on data entry. Data stored at the
LCTU will be checked for missing or unusual values
(range checks) and checked for consistency over time.
The LCTU will preserve the confidentiality of partici-
pants taking part in the study. Access to the final trial
dataset is granted by the written authorisation of the
Chief Investigator, CCK.
Participant retention and complete follow-up
The Trial Coordinator will produce reports on patient
withdrawals, losses to follow-up and the quantity of
missing CRFs/data across sites for review by LCTU busi-
ness meetings, the Trial Management Group (TMG),
Trial Steering Committee (TSC) and Independent Safety
and Data Monitoring Committee (ISDMC). Any prob-
lems identified will be discussed and remedial action
taken as necessary. Patients who withdraw from the trial
will be replaced, and any who deviate will be managed
on a case-by-case basis.
If a patient wishes to withdraw from trial treatment,
this will be acted upon immediately and will cause no
detrimental effect to them in receiving usual standard of
care. Following end of study biopsy, a single safety
follow-up is performed at ~ 2/52. There is no long-term
follow-up within the trial. All long-term follow-up will
be as per usual NHS practice.
Trial governance
Trial Coordinator (LCTU)
The LCTU will conduct central monitoring to ensure
patient safety and that the trial procedures, trial inter-
vention administration and laboratory and data collec-
tion processes meet both Sponsor and regulatory
requirements. This includes ensuring that all regulatory
and ethical approvals are in place before a site is opened,
and generation of periodic Central Monitoring Reports
for review by the Trial Management Group (TMG). The
LCTU will carry out audits of trial sites and laboratories
independent of the investigators and the Sponsor using
set procedures after the first patient is recruited and
after the tenth patient is recruited. The LCTU has a for-
malised Quality Management System in place for trial
Quality Assurance.
Trial Management Group
The Trial Management Group (TMG) will comprise of
the Chief Investigator, other lead investigators (clinical
and non-clinical) and members of the LCTU. The TMG
will be responsible for the day-to-day running and man-
agement of the trial and will meet approximately three
times per year.
Trial Steering Committee
The Trial Steering Committee (TSC) includes a minimum
of an independent Chairman; two additional independent
expert members in the field of breast cancer (one being a
statistician) and a lay/consumer representative, along with
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members of the Trial Management Group (TMG).
Among other things, the TSC takes responsibility for
monitoring and supervising the progress of the trial, con-
sidering recommendations from the Independent Safety
and Data Monitoring Committee (IDSMC) and advising
the TMG on all aspects of the trial as outlined in the TSC
charter. Further details on the TIP Trial TSC charter can
be obtained from the Trial Coordinator (https://www.lctu.
org.uk).
The ultimate decision for the continuation of the trial
lies with the TSC, and the TSC may stop the trial before
completion upon recommendation of the IDSMC.
Independent Data and Safety Monitoring Committee
The TIP Trial Independent Safety and Data Monitoring
Committee (IDSMC) is a multidisciplinary group inde-
pendent from the Sponsor and competing interests. The
IDSMC consists of an independent chairperson with
breast cancer and/or significant trial experience, plus two
further independent members: one statistician and at least
one clinician. They are responsible for safeguarding the in-
terests of trial participants, with interim monitoring of the
safety and efficacy of the interventions during the trial,
and for monitoring the overall progress and conduct of
the clinical trial as outlined in the IDSMC charter. Further
details on the TIP Trial IDSMC charter can be obtained
from the Trial Coordinator.
The IDSMC will first convene prior to the recruitment
of the first patient and will then define the required fre-
quency of subsequent meetings (at least annually). The
IDSMC will provide a recommendation to the Trial Steer-
ing Committee concerning the continuation of the study.
Safety monitoring
Rivaroxaban is an oral anticoagulant, with an associated
risk of bleeding, as with any anticoagulant. Unlike War-
farin, blood monitoring is not required. We will system-
ically collect data on all expected and unexpected
adverse events at each study visit, with Principal Investi-
gators required to assess and report them to the Trial
Coordinator throughout the whole trial process, from
trial entry through to follow-up. An adverse event term
must be provided for each adverse event, using the
terms listed in the Common Terminology Criteria for
Adverse Events v4.03 [58]. Investigators must report
serious adverse events (SAEs) within 24 h of the local
site becoming aware of the event. Adverse events related
to the study intervention will be reported in trial
publications.
This study may be terminated at the request of the
Chief Investigator, Independent Data and Safety Moni-
toring Committee or the Independent Ethics Committee
if, during the course of the study, concerns about the
safety emerge. Serious adverse events are relayed directly
to the Chief Investigator via the Trial Coordinator, with
all adverse events included in the Central Monitoring
Reports reviewed at Trial Management Group meetings.
Interim monitoring of safety is also carried out by the
IDSMC. The report of a serious adverse reaction or mul-
tiple adverse reaction incidences (depending on severity)
would constitute grounds for trial termination.
Dissemination
We aim to present the data at scientific and medical
conferences and to publish the results in a peer-
reviewed journal. Authorship guidelines will be as per
Recommendations for the Conduct, Reporting, Editing
and Publication of Scholarly work in Medical Journals,
International Committee of Medical Journal Editors
(ICMJE) [59]. We have no intended use of professional
writers.
Discussion
Ki67 is recognised as a marker of tumour proliferation
in trials of endocrine therapy. Short-term neoadjuvant
studies have demonstrated that only 2 weeks of pre-
operative endocrine therapy induces changes in Ki67
which predicts for treatment benefit and long-term sur-
vival outcome [51]. By using biomarkers, we will be able
to demonstrate the effectiveness of Rivaroxaban in the
clinical setting within 5 years, thereby providing an im-
proved clinical trials service to the patients recruited.
However, the measurement of Ki67 has its challenges as
there is substantial heterogeneity and variable levels of
validity in methods of assessment [57]. It is agreed that
we will use the immunohistochemistry (IHC) method
for determining Ki67 percentages. The IHC staining and
assessment of Ki67 will be performed on all trial samples
in one batch upon trial completion in an attempt to
minimise variability and increase accuracy.
The collection of fresh tumour tissue for mammo-
sphere analysis will not always be feasible, particularly in
patients with smaller tumours or who undergo a re-
search biopsy. Mammosphere analysis is therefore a sec-
ondary and exploratory outcome of the TIP trial.
However, if successful, it may allow assessment of the
value of fresh tissue in ex vivo analysis as a biomarker of
response.
This trial has been designed to minimise the chance of
haematoma following surgery or biopsy in the presence
of an anticoagulant. The terminal elimination half-life of
Rivaroxaban is 5 to 9 h in healthy subjects aged 20 to 45
years and 11 to 13 h in elderly patients aged 60 to 76
years [60]. Clinical guidelines recommend stopping the
drug in routine surgery patients at ≥ 24 h before surgery
for minor risk procedures [61]; therefore, a safe time
period, in patients with normal renal function, was taken
as 24 h. However, clinicians (surgeons or radiologists
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performing biopsies) are still advised of the randomisa-
tion so bleeding precautions can be maximised.
The trial was initially designed as a window-of-
opportunity pre-surgery study; however, with changing
clinical practice, increasingly ER-negative patients are
having neoadjuvant chemotherapy. Therefore, an
amendment to the study was submitted to allow inclu-
sion of neoadjuvant patients, with the post-trial biopsy
being an additional research biopsy. It is routine to
undergo radiological clip placement prior to commence-
ment of chemotherapy, to allow identification of the
tumour bed in the presence of complete radiological re-
sponse to NAC. Therefore, to minimise impact on trial
patients, the post-trial biopsy is performed at the time of
clip placement. This was assessed as acceptable by our
patient and public collaborators.
Trial status
Current protocol: Version 6, dated 10 October 2017
Important protocol modifications are communicated to
relevant parties by the trial coordinator by direct commu-
nication and via the LCTU Portal www.lctu.org.uk.
Recruitment start: June 2016
Expected recruitment end: September 2020
Open trial centres: Wythenshawe Hospital (Manches-
ter), Royal Bolton Hospital, Royal Liverpool University
Hospital, North Manchester General Hospital, St James’s
University Hospital Leeds, Arrow Park Hospital/Clatter-
bridge Cancer Centre (Wirral), Churchill Hospital (Ox-
ford); all United Kingdom.
Trial sponsor contact: Hayley Brooks, Oncology Clin-
ical Trials Manager, Manchester University NHS Foun-
dation Trust, Hayley.brooks@mft.nhs.uk
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04675-7.
Additional file 1. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents.
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